MRX vs. AAT, FINV, CASH, JBGS, ELME, STEW, PWP, WT, SYBT, and HMN
Should you be buying Medicis Pharmaceutical stock or one of its competitors? The main competitors of Medicis Pharmaceutical include American Assets Trust (AAT), FinVolution Group (FINV), Pathward Financial (CASH), JBG SMITH Properties (JBGS), Elme Communities (ELME), SRH Total Return Fund (STEW), Perella Weinberg Partners (PWP), WisdomTree (WT), Stock Yards Bancorp (SYBT), and Horace Mann Educators (HMN). These companies are all part of the "finance" sector.
Medicis Pharmaceutical (NYSE:MRX) and American Assets Trust (NYSE:AAT) are both small-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, valuation, dividends, earnings, institutional ownership, analyst recommendations, media sentiment, risk and community ranking.
American Assets Trust has a net margin of 12.05% compared to Medicis Pharmaceutical's net margin of 0.00%. American Assets Trust's return on equity of 4.60% beat Medicis Pharmaceutical's return on equity.
In the previous week, American Assets Trust had 1 more articles in the media than Medicis Pharmaceutical. MarketBeat recorded 1 mentions for American Assets Trust and 0 mentions for Medicis Pharmaceutical. American Assets Trust's average media sentiment score of 1.92 beat Medicis Pharmaceutical's score of 0.00 indicating that American Assets Trust is being referred to more favorably in the news media.
American Assets Trust received 227 more outperform votes than Medicis Pharmaceutical when rated by MarketBeat users. Likewise, 66.61% of users gave American Assets Trust an outperform vote while only 65.75% of users gave Medicis Pharmaceutical an outperform vote.
Medicis Pharmaceutical presently has a consensus price target of $26.29, suggesting a potential upside of 21.36%. American Assets Trust has a consensus price target of $22.00, suggesting a potential upside of 4.56%. Given Medicis Pharmaceutical's stronger consensus rating and higher possible upside, equities research analysts plainly believe Medicis Pharmaceutical is more favorable than American Assets Trust.
American Assets Trust has higher revenue and earnings than Medicis Pharmaceutical.
90.4% of American Assets Trust shares are held by institutional investors. 3.8% of Medicis Pharmaceutical shares are held by insiders. Comparatively, 37.3% of American Assets Trust shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Summary
American Assets Trust beats Medicis Pharmaceutical on 10 of the 13 factors compared between the two stocks.
Get Medicis Pharmaceutical News Delivered to You Automatically
Sign up to receive the latest news and ratings for MRX and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Medicis Pharmaceutical Competitors List
Related Companies and Tools
